Monograph Details
|
|
Hematology
> Thromboembolic disorders
|
|
PLAVIX |
| Manufacturer |
|
BMS/Sanofi Pharmaceuticals Partnership |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Platelet aggregation inhibitor. |
| Generic Name |
|
Clopidogrel (as bisulfate) 75mg, 300mg; tabs. |
| Indications |
|
Reduction of atherosclerotic events in: recent MI or stroke, peripheral arterial disease; non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) or ST-segment elevation acute MI; see literature. |
| Children |
|
Not recommended. |
| Adults |
|
75mg once daily. Non-ST-segment acute coronary syndrome (give with aspirin 75–325mg once daily): give one 300mg loading dose first. ST-segment elevation acute MI (give with aspirin, with or without thrombolytics): may start with or without a loading dose. |
| Contraindications |
|
Active pathologic bleeding (eg, peptic ulcer, intracranial hemorrhage). |
| Precautions |
|
Risk of bleeding (eg, surgery, ulcers, trauma, concomitant NSAIDs). Severe hepatic or renal disease. Consider discontinuing 5 days before elective surgery. Pregnancy (Cat.B). Nursing mothers: not recommended. |
| Interactions |
|
Caution with drugs that increase risk of bleeding (eg, NSAIDs, warfarin), and with drugs metabolized by CYP2C9 (eg, phenytoin, tolbutamide, tamoxifen, warfarin, torsemide, fluvastatin, many NSAIDs). |
| Adverse Reactions |
|
Bleeding, GI upset/ulcers, bruising, rash, pruritus, dizziness, headache; rare: thrombotic thrombocytopenic purpura, neutropenia, agranulocytosis. |
| How Supplied |
Tabs 75mg—30, 90, 500
300mg—4, 30, 100 |
|
|
|
|
